Swiss National Bank Has $1.09 Million Holdings in RadNet Inc. (NASDAQ:RDNT)

Swiss National Bank lifted its position in RadNet Inc. (NASDAQ:RDNT) by 4.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,200 shares of the medical research company’s stock after buying an additional 3,500 shares during the quarter. Swiss National Bank owned about 0.16% of RadNet worth $1,092,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in RadNet by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,581,140 shares of the medical research company’s stock valued at $16,081,000 after buying an additional 12,736 shares during the period. Cortina Asset Management LLC raised its stake in RadNet by 32.5% in the 2nd quarter. Cortina Asset Management LLC now owns 1,167,254 shares of the medical research company’s stock valued at $16,096,000 after acquiring an additional 286,388 shares during the period. Global Alpha Capital Management Ltd. lifted its holdings in RadNet by 63.1% during the 1st quarter. Global Alpha Capital Management Ltd. now owns 897,148 shares of the medical research company’s stock valued at $11,116,000 after purchasing an additional 347,100 shares during the last quarter. Royce & Associates LP lifted its holdings in RadNet by 33.8% during the 1st quarter. Royce & Associates LP now owns 364,423 shares of the medical research company’s stock valued at $4,515,000 after purchasing an additional 92,000 shares during the last quarter. Finally, Cadence Capital Management LLC lifted its holdings in RadNet by 1.8% during the 1st quarter. Cadence Capital Management LLC now owns 251,261 shares of the medical research company’s stock valued at $3,113,000 after purchasing an additional 4,433 shares during the last quarter. Institutional investors and hedge funds own 61.62% of the company’s stock.

In other news, VP Mark Stolper sold 20,703 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $15.15, for a total value of $313,650.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael L. Md Sherman sold 30,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $15.19, for a total transaction of $455,700.00. Following the completion of the sale, the director now directly owns 259,083 shares of the company’s stock, valued at approximately $3,935,470.77. The disclosure for this sale can be found here. Insiders have sold a total of 142,370 shares of company stock worth $2,071,305 in the last quarter. Company insiders own 6.10% of the company’s stock.

Shares of RadNet stock traded down $0.07 on Wednesday, hitting $14.09. The stock had a trading volume of 13,206 shares, compared to its average volume of 235,276. RadNet Inc. has a twelve month low of $9.97 and a twelve month high of $16.54. The business’s 50 day moving average is $14.56 and its two-hundred day moving average is $13.59. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 5.09. The stock has a market cap of $698.27 million, a price-to-earnings ratio of 21.35, a price-to-earnings-growth ratio of 5.63 and a beta of 0.93.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported $0.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.02). The firm had revenue of $289.10 million for the quarter, compared to analyst estimates of $272.36 million. RadNet had a return on equity of 18.91% and a net margin of 3.33%. The business’s revenue for the quarter was up 18.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.11 earnings per share. As a group, equities analysts predict that RadNet Inc. will post 0.33 earnings per share for the current fiscal year.

RDNT has been the topic of several research reports. TheStreet downgraded shares of RadNet from a “b-” rating to a “c” rating in a report on Tuesday, June 4th. BidaskClub cut shares of RadNet from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 28th. Finally, Zacks Investment Research downgraded shares of RadNet from a “hold” rating to a “sell” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. RadNet currently has a consensus rating of “Hold” and a consensus price target of $17.75.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Recommended Story: What is meant by a buy rating?

Institutional Ownership by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.